Matthew Blischak
Chief Executive Officer at FINCH THERAPEUTICS GROUP, INC.
Profile
Matthew P.
Blischak is currently the President, Chief Executive Officer & Secretary at Finch Therapeutics Group, Inc. Prior to his current position, he worked as the Vice President-Intellectual Property at Roivant Sciences, Inc. from 2018 to 2023.
Mr. Blischak completed his undergraduate degree at Case Western Reserve University and his graduate degrees at The Johns Hopkins University and American University Washington College of Law.
Matthew Blischak active positions
| Companies | Position | Start |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Chief Executive Officer | 2023-05-15 |
Former positions of Matthew Blischak
| Companies | Position | End |
|---|---|---|
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Corporate Officer/Principal | 2023-03-31 |
Training of Matthew Blischak
| Case Western Reserve University | Undergraduate Degree |
| The Johns Hopkins University | Graduate Degree |
| American University Washington College of Law | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Private companies | 1 |
|---|---|
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
- Stock Market
- Insiders
- Matthew Blischak
